KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short term Debt: 2009-2016

Historic Short term Debt for Vertex Pharmaceuticals (VRTX) over the last 3 years, with Dec 2016 value amounting to $300.0 million.

  • Vertex Pharmaceuticals' Short term Debt rose 320.78% to $300.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $300.0 million, marking a year-over-year increase of 320.78%. This contributed to the annual value of $300.0 million for FY2016, which is 320.78% up from last year.
  • Vertex Pharmaceuticals' Short term Debt amounted to $300.0 million in Q4 2016, which was up 0.76% from $297.8 million recorded in Q3 2016.
  • Over the past 5 years, Vertex Pharmaceuticals' Short term Debt peaked at $300.0 million during Q4 2016, and registered a low of $14.2 million during Q4 2014.
  • Moreover, its 3-year median value for Short term Debt was $108.8 million (2015), whereas its average is $140.3 million.
  • Data for Vertex Pharmaceuticals' Short term Debt shows a peak YoY spiked of 416.82% (in 2016) over the last 5 years.
  • Vertex Pharmaceuticals' Short term Debt (Quarterly) stood at $14.2 million in 2014, then soared by 401.87% to $71.3 million in 2015, then spiked by 320.78% to $300.0 million in 2016.
  • Its last three reported values are $300.0 million in Q4 2016, $297.8 million for Q3 2016, and $221.6 million during Q2 2016.